Pharmacokinetics and serum concentrations of antimycobacterial drugs in adult Turkish patients

International Journal of Tuberculosis and Lung Disease

Volumn 17, Issue 11, 2013, Pages 1442-1447

  Babalik, Aylin ^a   Ulus, I H ^b   Bakirci, N ^b   Kuyucu, T ^a   Arpag, H ^a   Dagyildiz, L ^a   Carpaner E ^c  

^a Sureyyapasa Chest Diseases and Thoracic Surgery Training and Research Hospital   (Turkey)

^b ACIBADEM UNIVERSITY   (Turkey)

^c Kaan Med Toxicology Laboratory   (Turkey)

Author keywords

Ethambutol; Isoniazid; Pyrazinamide; Rifampicin; Subtherapeutic levels

Indexed keywords

ANTIMYCOBACTERIAL AGENT; ETHAMBUTOL; ISONIAZID; MIAMBUTOL; PIRAZINID; PYRAZINAMIDE; RIFAMPICIN; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG MONITORING; ETHNIC GROUP; FEMALE; HUMAN; LUNG TUBERCULOSIS; MALE; MAXIMUM PLASMA CONCENTRATION; PRIORITY JOURNAL; SPUTUM ANALYSIS; TREATMENT RESPONSE; TURKEY (REPUBLIC); TURKISH;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; ANTITUBERCULAR AGENTS; AREA UNDER CURVE; DIRECTLY OBSERVED THERAPY; DRUG MONITORING; ETHAMBUTOL; FEMALE; HALF-LIFE; HUMANS; ISONIAZID; MALE; MIDDLE AGED; PYRAZINAMIDE; RIFAMPIN; TUBERCULOSIS, PULMONARY; TURKEY; YOUNG ADULT;

EID: 84888112166     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: 10.5588/ijtld.12.0771     Document Type: Article

References (35)

1. World Health Organization. Global tuberculosis control: the burden of disease caused by tuberculosis. WHO/HTM/TB/2011.16. Geneva, Switzerland: WHO, 2011.
2. World Health Organization. Treatment of tuberculosis guidelines. 4th ed. WHO/HTL/TB/2009.420. Geneva, Switzerland: WHO, 2009.
3. American Thoracic Society/Infectious Disease Society of America/Centers for Disease Control. Treatment of tuberculosis. Am J Respir Crit Care Med 2003; 167: 603-662.
4. Long R L, Ellis E. Canadian tuberculosis standards, 6th ed. Toronto, ON, Canada: Canadian Lung Association, Public Health Agency of Canada, Tuberculosis Prevention and Control, 2007.
5. Özkara S, Aktaş Z, Özkan S, Ecevit H. [A guidebook for tuberculosis control in Turkey]. Ankara, Turkey: Tuberculosis Control Department, 2003. [Turkish]
6. Bozkurt H, Türkkan M H, Musaonbaşioǧlu S, Yildirim A, Baykal F. Türkiye'de Verem Savaş raporu 2011. Ankara, Turkey: Verem Savaş Dairesi Başkanliǧi, 2011. [Turkish]
7. Holdiness M. Clinical pharmacokinetics of the anti-tuberculosis drugs. Clin Pharmacokinet 1984; 9: 511-544.
8. Peloquin C A, Namdar R, Dodge A A, Nix D E. Pharmacokinetics of isoniazid under fasting conditions, with food and with antacids. Int J Tuberc Lung Dis 1999; 3: 703-710. (Pubitemid 29378471)
9. Peloquin C A, Namdar R, Dodge A A, Nix D E. Pharmacokinetics of rifampin under fasting conditions, with food and with antiacid. Chest 1999; 115: 12-18. (Pubitemid 29047048)
10. Peloquin C A. Pharmacological issues in the treatment of tuberculosis. Ann NY Acad Sci 2001; 953: 157-164. (Pubitemid 34072990)
11. Peloquin C A. Therapeutic drug monitoring in the treatment of tuberculosis. Drugs 2002; 62: 2169-2183. (Pubitemid 35252827)
12. Panchagnula R, Sancheti P, Rungta S, Agrawal S, Kaul C L. Evaluation of bioequivalence of isoniazid and pyrazinamaide in three and four drugs fixed combinations using WHO simplified protocol. Pharmacol Res 2003; 48: 383-387. (Pubitemid 36945337)
13. Agrawal S, Singh I, Kaur K J, Bhade S R, Kaul C L, Panchagnula R. Comparative bioavailability of rifampicin, isoniazid and pyrazinamide from a four-drug fixed-dose combination with separate formulations at the same dose levels. Int J Pharm 2004; 276: 41-49. (Pubitemid 38542986)
14. Tappero J W, Bradford W Z, Agerton T B, et al. Serum concentrations of antibacterial drugs in patients with pulmonary tuberculosis in Botswana. Clin Infect Dis 2005; 41: 461-469. (Pubitemid 41099637)
15. van Crevel R, Alisjahbana B, de Lange W C M, et al. Low plasma concentrations of rifampicin in tuberculosis patients in Indonesia. Int J Tuberc Lung Dis 2002; 6: 497-502. (Pubitemid 34601866)
16. McIlleron H, Walsh P, Burger A, Norman J, Folb P I, Smith P. Determinants of rifampin, isoniazid, pyrazinamaide and ethambutol pharmacokinetics in a cohort of tuberculosis patients. Antimicrob Agents Chemother 2006; 50: 1170-1077.
17. Wilkins J J, Langdon G, McIlleron H, Pillai G, Smith P J, Simonsson U S H. Variability in the population pharmacokinetics of pyrazinamide in South African tuberculosis patients. Eur J Clin Pharmacol 2006; 62: 727-735. (Pubitemid 44289503)
18. Lin M-Y, Lin S-J, Chan L-C, Lu Y-C. Impact of food and antacids on the pharmacokinetics of anti-tuberculosis drugs: systematic review and meta-analysis. Int J Tuberc Lung Dis 2010; 14: 806-818.
19. Peloquin C A, Machee A A, Berning S E. Malabsorption of antimicrobial medications. N Engl J Med 1993; 329: 1122-1123.
20. Mehta J B, Shantaveerapa H, Byrd J R P Jr, Morton S E, Fountain F. Utility of rifampin blood levels in the treatment and follow-up of active pulmonary tuberculosis in patients who were slow to respond to routine directly observed therapy. Chest 2001; 120: 1520-1524. (Pubitemid 33078467)
21. Pinheiro V G F, Ramos L M A, Monteiro H S, et al. Intestinal permeability and malabsorption of rifampin and isoniazid in active pulmonary tuberculosis. Braz J Infect Dis 2006; 10: 374-379. (Pubitemid 46585565)
22. Kimerling M E, Phillips P, Patterson P, Hall M, Robinson A, Dunlap N E. Low serum anti-mycobacterial drug levels in non-HIV-infected tuberculosis patients. Chest 1998; 113: 1178-1183. (Pubitemid 28223801)
23. Weiner M, Burman W, Vernon A, et al. Low isoniazid concentrations and outcome of tuberculosis treatment with onceweekly isoniazid and rifapentine. Am J Respir Crit Care Med 2003; 167: 1341-1347. (Pubitemid 36609717)
24. Weiner M, Benator D, Burman W, et al. Association between acquired rifampicin resistance and the pharmacokinetics of rifabutin and isoniazid among patients with HIV and tuberculosis. Clin Infect Dis 2005; 40: 1481-1491. (Pubitemid 40628637)
25. Um S-W, Lee S W, Kwon S Y, et al. Low serum concentrations of anti-tuberculosis drugs and determinants of their serum levels. Int J Tuberc Lung Dis 2007; 11: 972-978. (Pubitemid 47425023)
26. Chideya S, Winston C A, Peloquin C A, et al. Isoniazid, rifampin, ethambutol and pyrazinamide pharmacokinetics and treatment outcomes among a predominantly HIV-infected cohort of adults with tuberculosis from Botswana. Clin Infec Dis 2009; 48: 1685-1694.
27. Babalik A, Mannix S, Francis D, Menzies D. Therapeutic drug monitoring in the treatment of active tuberculosis. Can Respir J 2011; 18: 225-229.
28. Unsalan S, Sancar M, Bekce B, et al. Therapeutics monitoring of isoniazid, pyrazinamide and rifampicin in tuberculosis patients using LC. Chromatographia 2005; 61: 505-598.
29. Chenevier P, Massias L, Geylard D, Farinotti R. Determination of ethambutol in plasma by high-performance liquid chromatography after pre-column derivatization. J Chromatography B 1998; 708: 310-315. (Pubitemid 28239921)
30. Ulus I H, Buyukuysal L, Aydin S, Mogol E, Gurun M S, Kiran B K. Comparison of bioavailability of sultamicillin in healthy volunteers following oral administration of two different tablet formulations. Uludag Univ Med J 1994; 1: 59-64.
31. Buyukuysal L, Ulus I H, Aydin S, Mogol E, Kiran B K. Comparison of relative bioavailability and pharmacokinetics characteristics of three different tablet formulations of amlodipine in healthy volunteers. Uludag Univ Med J 1994; 1: 65-70.
32. Barroso E C, Pinheiro V G F, Façanha M C, et al. Serum concentrations of rifampin, isoniazid and intestinal absorption, permeability in patients with multidrug resistant tuberculosis. Am J Trop Med Hyg 2009; 81: 322-329.
33. Kinzig-Schippers M, Tomalik-Scharte D, Jetter A, et al. Should we use N-acetyltransferase type 2 genotyping to personalize isoniazid doses? Antimicrob Agents Chemother 2005; 49: 1733-1738. (Pubitemid 40631582)
34. Ozbek Y K, Ozturk T, Tuzuner B M, et al. Combined effect of CYP1B1 codon 432 polymorphisim and N-acetyltransferase 2 slow acetylator phenotypes in relation to breast cancer in the Turkish population. Anticancer Res 2010; 30: 2885-2890.
35. Ray J, Gardiner I, Marriott D. Managing anti-tuberculosis drug therapy by therapeutic drug monitoring of rifampicin and isoniazid. Inter Med J 2003; 33: 229-234. (Pubitemid 36718380)